Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Medistim Director's Dealing 2026

Apr 17, 2026

3662_rns_2026-04-17_6ff7a1b1-46c9-4811-ba0d-a1627a3bcd76.html

Director's Dealing

Open in viewer

Opens in your device viewer

CEO share program- Correction

CEO share program- Correction

It was reported earlier today that K2 Consulting AS had 44500 after the transfer of shares to the CEO controlled company. The correct number of share after the transfer are 43500 shares. After the transfer the CEO controls 90583 as reported earlier.

More from Medistim

Major Shareholding Notification 2026
May 12
Major Shareholding Notification 2026
May 12
Notice of Dividend Amount 2026
May 7
Interim / Quarterly Report 2026
May 7
Interim / Quarterly Report 2026
May 7
Interim / Quarterly Report 2026
May 7
Declaration of Voting Results & Voting Rights Announcements 2026
May 6
Notice of Dividend Amount 2026
May 6
Notice of Dividend Amount 2026
Apr 30
Report Publication Announcement 2026
Apr 28
View all filings →